Globally, peramivir is an intravenous neuraminidase inhibitor approved for influenza in the US (Rapivab), Japan and South Korea (Rapiacta), China (Xiaoruiping), and several other markets. Demand centers on hospitalized and severe cases where oral drugs are impractical. Sales are strongly seasonal and follow flu outbreaks. Pandemic stockpiling adds a steadier layer of demand.

According to The Insight Partners, Peramivir Market size is expected to reach US$ 335.48 million by 2034 from US$ 135.92 million in 2025, registering a CAGR of 10.56% during the forecast period from 2026 to 2034.

The global Peramivir Market is experiencing significant growth, driven by the rising prevalence of influenza infections across the world and increasing demand for effective antiviral treatments. Market expansion is further supported by ongoing advancements in antiviral drug development, greater awareness of influenza management, and improved access to healthcare services in emerging economies. The growing incidence of seasonal influenza outbreaks, coupled with the need for timely and effective treatment options, is creating favorable opportunities for the continued growth of the Peramivir Market.

 Get a Sample PDF - https://www.theinsightpartners.com/sample/TIPRE00014944

Key Market Drivers Fueling Peramivir Market Growth

One of the major drivers supporting the expansion of the Peramivir market is the growing incidence of influenza-related complications. Seasonal influenza continues to pose a significant public health challenge globally, resulting in millions of severe cases and substantial healthcare costs each year. Peramivir, an intravenous neuraminidase inhibitor, offers healthcare professionals a valuable treatment option, particularly for hospitalized patients and individuals who cannot tolerate oral antiviral medications.

Another important growth factor is the increasing focus on pandemic preparedness and infectious disease management. Governments and healthcare organizations worldwide are strengthening stockpiling strategies for antiviral medications to ensure rapid response during influenza outbreaks. This proactive approach is generating increased demand for effective antiviral agents such as Peramivir.

The growing geriatric population also plays a crucial role in market expansion. Older adults are more susceptible to severe influenza infections and associated complications due to weakened immune systems. As global populations continue to age, the demand for advanced influenza treatment options is expected to rise significantly, supporting long-term market growth.

Rising Adoption of Intravenous Antiviral Therapies

The healthcare industry's shift toward effective hospital-based antiviral treatments is creating new opportunities for Peramivir manufacturers. Unlike oral antiviral drugs, Peramivir can be administered intravenously, making it particularly useful in critical care settings and emergency departments. This advantage is driving its adoption among healthcare providers treating severe influenza cases.

Additionally, increasing hospital admissions associated with influenza-related respiratory complications are encouraging physicians to utilize rapid-acting antiviral therapies. The ability of Peramivir to provide targeted treatment through a single intravenous dose enhances patient compliance and treatment efficiency, further supporting market expansion.

Technological Advancements and Research Initiatives

Ongoing research and development activities aimed at improving antiviral drug efficacy and safety are positively influencing the Peramivir market. Pharmaceutical companies are investing in clinical studies and innovative formulation technologies to enhance treatment outcomes and broaden therapeutic applications.

The growing emphasis on precision medicine and personalized treatment strategies is also expected to create new growth avenues. Advances in diagnostic technologies are enabling earlier identification of influenza infections, allowing timely administration of antiviral therapies such as Peramivir. These developments are anticipated to improve patient outcomes and drive increased market adoption.

Expanding Healthcare Infrastructure in Emerging Markets

Emerging economies across Asia Pacific, Latin America, and the Middle East are experiencing significant improvements in healthcare infrastructure and access to advanced therapeutics. Governments are investing heavily in healthcare modernization, disease surveillance programs, and public health initiatives aimed at reducing the burden of infectious diseases.

As awareness regarding influenza treatment increases and healthcare accessibility improves, demand for innovative antiviral drugs is expected to rise. Furthermore, expanding pharmaceutical distribution networks and favorable regulatory frameworks are enabling greater market penetration for Peramivir manufacturers in these regions.

Competitive Landscape and Leading Market Players

The Peramivir market is characterized by strategic collaborations, product development initiatives, and efforts to expand geographic presence. Companies are focusing on strengthening their antiviral portfolios and enhancing production capabilities to meet growing global demand.

Some of the prominent players operating in the Peramivir market include:

• Green Cross Pharma
• Shionogi Co.
• Neopharm
• Moksha8 Pharma
• NT Pharma
• Merck
• Hikma Pharmaceuticals
• Hunan Nucien Pharmaceutical Co., Ltd.
• SCOLR Pharma
• BioCryst Pharmaceuticals, Inc.

These companies continue to invest in research, regulatory approvals, and strategic partnerships to strengthen their market positions and capitalize on emerging growth opportunities.

Future Outlook

The outlook for the global Peramivir market remains highly positive through 2034. Increasing influenza prevalence, rising demand for effective antiviral therapies, expanding healthcare infrastructure, and growing investments in infectious disease management are expected to drive sustained market growth. Furthermore, advancements in antiviral drug development and supportive government initiatives aimed at pandemic preparedness will continue to create favorable opportunities for market participants.

With healthcare systems worldwide prioritizing rapid and effective influenza treatment solutions, Peramivir is expected to play an increasingly important role in the global antiviral therapeutics landscape over the coming decade.

About Us

The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us

Ankit Mathur | The Insight Partners
E-mail: ankit.mathur@theinsightpartners.com
Phone: +1-646-491-9876

Also Available in : Korean | German | Japanese | French | Chinese | Italian | Spanish